American Thyroid Association
The latest news from the ATA Annual Meeting, with physician perspective, researcher interviews and clinician insight.
expand
SPONSORED CONTENT
October 24, 2022
2 min read
Save
Few adults with thyroid eye disease receiving teprotumumab require second course
Less than 5% of adults with thyroid eye disease who completed a full course of teprotumumab therapy required an additional course of the agent, according to a presenter at the American Thyroid Association annual meeting.